23Andme Holding Co
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.08
- Today's High:
- $1.14
- Open Price:
- $1.12
- 52W Low:
- $0.987
- 52W High:
- $3.5
- Prev. Close:
- $1.14
- Volume:
- 2894557
Company Statistics
- Market Cap.:
- $529.19 million
- Book Value:
- 1.431
- Revenue TTM:
- $295.84 million
- Operating Margin TTM:
- -114.75%
- Gross Profit TTM:
- $132.95 million
- Profit Margin:
- -110.45%
- Return on Assets TTM:
- -21.95%
- Return on Equity TTM:
- -42.72%
Company Profile
23Andme Holding Co had its IPO on 2020-11-23 under the ticker symbol ME.
The company operates in the Healthcare sector and Diagnostics & Research industry. 23Andme Holding Co has a staff strength of 758 employees.
Stock update
Shares of 23Andme Holding Co opened at $1.12 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.08 - $1.14, and closed at $1.12.
This is a -1.75% slip from the previous day's closing price.
A total volume of 2,894,557 shares were traded at the close of the day’s session.
In the last one week, shares of 23Andme Holding Co have increased by 0%.
23Andme Holding Co's Key Ratios
23Andme Holding Co has a market cap of $529.19 million, indicating a price to book ratio of 1.7123 and a price to sales ratio of 4.1168.
In the last 12-months 23Andme Holding Co’s revenue was $295.84 million with a gross profit of $132.95 million and an EBITDA of $-308883008. The EBITDA ratio measures 23Andme Holding Co's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, 23Andme Holding Co’s operating margin was -114.75% while its return on assets stood at -21.95% with a return of equity of -42.72%.
In Q2, 23Andme Holding Co’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5.7%.
23Andme Holding Co’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 23Andme Holding Co’s profitability.
23Andme Holding Co stock is trading at a EV to sales ratio of 3.6082 and a EV to EBITDA ratio of -3.7245. Its price to sales ratio in the trailing 12-months stood at 4.1168.
23Andme Holding Co stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $871.20 million
- Total Liabilities
- $118.91 million
- Operating Cash Flow
- $-2695000.00
- Capital Expenditure
- $2.70 million
- Dividend Payout Ratio
- 0%
23Andme Holding Co ended 2024 with $871.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $871.20 million while shareholder equity stood at $675.49 million.
23Andme Holding Co ended 2024 with $0 in deferred long-term liabilities, $118.91 million in other current liabilities, 47000.00 in common stock, $-1611008000.00 in retained earnings and $351.74 million in goodwill. Its cash balance stood at $314.35 million and cash and short-term investments were $314.35 million. The company’s total short-term debt was $7,823,000 while long-term debt stood at $0.
23Andme Holding Co’s total current assets stands at $360.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.12 million compared to accounts payable of $12.75 million and inventory worth $11.82 million.
In 2024, 23Andme Holding Co's operating cash flow was $-2695000.00 while its capital expenditure stood at $2.70 million.
Comparatively, 23Andme Holding Co paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.12
- 52-Week High
- $3.5
- 52-Week Low
- $0.987
- Analyst Target Price
- $4.5
23Andme Holding Co stock is currently trading at $1.12 per share. It touched a 52-week high of $3.5 and a 52-week low of $3.5. Analysts tracking the stock have a 12-month average target price of $4.5.
Its 50-day moving average was $1.5 and 200-day moving average was $2.09 The short ratio stood at 10.71 indicating a short percent outstanding of 0%.
Around 500% of the company’s stock are held by insiders while 4665.4% are held by institutions.
Frequently Asked Questions About 23Andme Holding Co
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company’s therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.